PLC Systems Inc. (OTC:PLCSF) is touting more results from a clinical study of its RenalGuard contrast-induced nephropathy treatment.
CIN is a form of acute renal failure caused by exposure to contrast media agents during image-guided cardiology and radiology procedures. The Franklin, Mass.-based company said data on 105 patients with chronic kidney disease indicate that only 4 percent of the patients treated with RenalGuard acquired the malady. The results, presented at last month’s American Heart Assn. Scientific Sessions 2009, are consistent with expectations set by the company after preliminary results were released in August.
The most recent results also showed that the incidence of in-hospital complications was 6 percent, compared to an 18 percent incident rate for the control group.
During its quarterly earnings release last month, CEO Mark Tauscher said the company believes the positive data will help drive more distribution deals like the five-year pact it signed with Brazil’s Discomed Comercio de Produtos Hospitalares Ltda.
The Franklin, Mass.-based device maker reported a third-quarter net loss of $358,000 on sales of $1 million, compared with a net loss of $285,000 on sales of $1.6 million during the same period last year.